Session

PP 05 IBD (Posters)

CLINICAL EFFICACY, THERAPEUTIC DRUG MONITORING AND NOCEBO EFFECT FOLLOWING NON-MEDICAL BIOSIMILAR SWITCH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE OBSERVATIONAL STUDY
CLINICAL EFFICACY, THERAPEUTIC DRUG MONITORING AND NOCEBO EFFECT FOLLOWING NON-MEDICAL BIOSIMILAR SWITCH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE OBSERVATIONAL STUDY

PP 05 IBD (Posters)  et al.

THE ROLE OF VITAMIN D STATUS ON EFFECTIVENESS OF BIOLOGIC THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE ROLE OF VITAMIN D STATUS ON EFFECTIVENESS OF BIOLOGIC THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

IMPLICATIONS OF TIOGUANINE DOSING IN IBD PATIENTS WITH A TPMT DEFICIENCY
IMPLICATIONS OF TIOGUANINE DOSING IN IBD PATIENTS WITH A TPMT DEFICIENCY

PP 05 IBD (Posters)  et al.

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

PP 05 IBD (Posters)  et al.

PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN REMODELING CAN EVALUATE FIBROGENESIS IN AN IN VITRO COLONIC SCAR-IN-A-JAR MODEL
PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN REMODELING CAN EVALUATE FIBROGENESIS IN AN IN VITRO COLONIC SCAR-IN-A-JAR MODEL

PP 05 IBD (Posters)  et al.

HYPOPHOSPHATAEMIA PRIOR TO INTRAVENOUS IRON TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: IS IT MORE COMMON THAN IN THE GENERAL POPULATION?
HYPOPHOSPHATAEMIA PRIOR TO INTRAVENOUS IRON TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: IS IT MORE COMMON THAN IN THE GENERAL POPULATION?

PP 05 IBD (Posters)  et al.

PREDICTORS OF AN EARLY SEVERE DISEASE COURSE OF NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES- FINDINGS FROM A DANISH POPULATION-BASED INCEPTION COHORT (IBD PROGNOSIS STUDY)
PREDICTORS OF AN EARLY SEVERE DISEASE COURSE OF NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES- FINDINGS FROM A DANISH POPULATION-BASED INCEPTION COHORT (IBD PROGNOSIS STUDY)

PP 05 IBD (Posters)  et al.

CRYPT-VILLUS DYNAMICS POST-DSS EXPOSURE IN MURINE COLITIS MODEL OF INFLAMMATORY BOWEL DISEASE
CRYPT-VILLUS DYNAMICS POST-DSS EXPOSURE IN MURINE COLITIS MODEL OF INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

LIPIDOMIC ANALYSIS OF FAECES FROM PATIENTS WITH ULCERATIVE COLITIS UNDERGOING FAECAL MICROBIOTA TRANSPLANTATION PREDICTS TREATMENT RESPONSE
LIPIDOMIC ANALYSIS OF FAECES FROM PATIENTS WITH ULCERATIVE COLITIS UNDERGOING FAECAL MICROBIOTA TRANSPLANTATION PREDICTS TREATMENT RESPONSE

PP 05 IBD (Posters)  et al.

STUDY OF ACTIVE SWITCHING FROM TOFACITINIB TO USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS
STUDY OF ACTIVE SWITCHING FROM TOFACITINIB TO USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE CAN TOLERATE A HIGH-FIBER, LOW-FAT DIET AND EXPERIENCE AN IMPROVEMENT IN SYMPTOMS: RESULTS OF A CATERED DIET INTERVENTION STUDY
PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE CAN TOLERATE A HIGH-FIBER, LOW-FAT DIET AND EXPERIENCE AN IMPROVEMENT IN SYMPTOMS: RESULTS OF A CATERED DIET INTERVENTION STUDY

PP 05 IBD (Posters)  et al.

RATIONAL SELECTION OF COMBINATION THERAPY FOR INFLAMMATORY BOWEL DISEASE TREATMENT USING AN ESTABLISHED PRECLINICAL MODEL
RATIONAL SELECTION OF COMBINATION THERAPY FOR INFLAMMATORY BOWEL DISEASE TREATMENT USING AN ESTABLISHED PRECLINICAL MODEL

PP 05 IBD (Posters)  et al.

EXAMINING THE ROLE OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) TO INDUCE REMISSION IN RESISTANT ULCERATIVE PROCTITIS (UP)
EXAMINING THE ROLE OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) TO INDUCE REMISSION IN RESISTANT ULCERATIVE PROCTITIS (UP)

PP 05 IBD (Posters)  et al.

ROLE OF EARLY IMMUNOMODULATOR OR BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN INTESTINAL BEHÇET’S DISEASE
ROLE OF EARLY IMMUNOMODULATOR OR BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN INTESTINAL BEHÇET’S DISEASE

PP 05 IBD (Posters)  et al.

THE RISK OF MILD, MODERATE AND SEVERE INFECTIONS IN IBD PATIENTS: RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL COHORT STUDY - PRIQ
THE RISK OF MILD, MODERATE AND SEVERE INFECTIONS IN IBD PATIENTS: RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL COHORT STUDY - PRIQ

PP 05 IBD (Posters)  et al.

LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS
LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS

PP 05 IBD (Posters)  et al.

A HIGHER RED BLOOD CELL METHOTREXATE POLYGLUTAMATE 3 CONCENTRATION IS ASSOCIATED WITH METHOTREXATE DRUG-SURVIVAL IN PATIENTS WITH CROHN’S DISEASE
A HIGHER RED BLOOD CELL METHOTREXATE POLYGLUTAMATE 3 CONCENTRATION IS ASSOCIATED WITH METHOTREXATE DRUG-SURVIVAL IN PATIENTS WITH CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY
PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY

PP 05 IBD (Posters)  et al.

IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

PP 05 IBD (Posters)  et al.

HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB
HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB

PP 05 IBD (Posters)  et al.

Item 41 - 60 / 826
1 2
3
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42